Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer - Wikidata - awgldk - TriplyDB

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

http://www.wikidata.org/entity/Q26772969

about

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists Twenty years of anti-HER2 therapy-associated cardiotoxicity Precision medicine in breast cancer: reality or utopia?An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors Lauren classification and individualized chemotherapy in gastric cancer.Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.mTOR function and therapeutic targeting in breast cancer.Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Targeting the mTOR pathway in breast cancer.Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer.ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab.Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis.Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer.Activating HER2 mutations as emerging targets in multiple solid cancers.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

P2860

Q26747729-55B09440-A6B7-4007-9ADF-ED83EE77847A Q28072513-332090A2-66A9-44C9-861A-820F1DAD7315 Q28078111-C337C979-B489-4B99-A13D-796F62B0F4C7 Q28079391-3529ADB9-180C-40F0-BADE-CC452D8172ED Q33809114-2AAE6FB5-3395-4205-B7AF-EF21D11D4DFA Q36114109-7DFCD77A-3E4D-4542-8634-9690B1297426 Q36283885-F0576C63-877A-473B-8D1B-E7EC7A4B55A3 Q36824887-732B9F25-B70D-4D95-8943-C7C6EAA315C9 Q37547952-626C011E-60F6-41E7-A4F0-400E7FB9637B Q37578368-01149B2A-64CE-42FA-9A3F-9FB024F2C690 Q37602839-D6BBD7C6-B167-42CB-9A85-3598B00882DF Q37660979-3E1CCE5C-E2C9-4CAA-8357-401FDCF638D5 Q37699360-EFCB60A1-D5C8-491C-A8F2-4D92B8C78A87 Q37743486-DF44248A-F393-4821-B8F0-D92E32CA0CFA Q38703402-B2F331C1-AF58-4649-A6B3-F26A6871DDEB Q38729111-ED5927C2-2209-41C6-BC25-AB2FCF9EFBAF Q39390640-EBE17CCD-6003-4892-A6F6-AF1D3968996E Q39831543-D033BCC4-42F1-451B-96F8-4A7F15CCE4C1 Q40229111-63B87A36-EF19-4E59-BF4C-EDAE1B11F750 Q41190480-3CA63C32-D627-40DB-B3FD-011C78F8AEA5 Q44249512-63A42574-73FC-492D-80BC-5DFDB26C05E8 Q47114739-07C52A6B-4966-440A-A632-1B097DD5860E Q47143199-EFBFEB47-3580-4DBC-A6C6-340BD79FAA4D Q47435154-37F495CF-BE15-410A-9DA5-179246F5FC97 Q47554862-5ED67A72-6F45-4DCE-BAC8-EB0A7A5BE5BB Q54977835-B3259112-C1C4-4EDD-99CF-1FC539943ABD Q54986604-0F99E35B-CE24-4E8B-B98B-7DCE3E8C59AC Q55240690-0727DA3D-DEB5-40FB-8B7D-6BBC5825D9C9 Q58709253-1D9B469D-C956-4D89-B819-47618A519E28 Q59128232-120AAF93-D480-46AC-9875-8A8FCFC3A8DC

P2860

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

http://www.wikidata.org/entity/Q26772969

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@ast

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@en

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@nl

type

label

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@ast

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@en

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@nl

prefLabel

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@ast

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@en

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@nl

P1433

Q26772969-936DEFDE-F5C1-48F4-A2B4-BDA5477FD68F

P1476

Q26772969-09F27E6F-4985-41B7-AD12-3C0D65CB07AA

P2093

Q26772969-75532286-F83F-4EFF-9ED2-2782141A0285

Q26772969-94F39D9C-77A0-4C3E-B43D-ED5FD2BAE10D

Q26772969-97D995C0-CD91-41BD-8F1D-D6AE6AAD383E

Q26772969-D67CAE9F-03B8-4463-98C9-A3FD1A0F20A2

P275

Q26772969-27AE452F-34D9-4EEE-A78D-9174965610C9

P2860

Q26772969-0056D449-7D08-44DD-9033-F886E5234C8D

Q26772969-00D54E94-8D72-4454-A988-51F6FA479160

Q26772969-04C1BA18-A377-442B-9F09-47136C0B48EA

Q26772969-053BD45D-8EC5-4AD2-966C-86F283AF071B

Q26772969-0914E3AB-2466-4C4C-9237-0598A62DFDE0

Q26772969-0A59994D-75A6-48DA-A434-0B68657F9A5B

Q26772969-0ACDCDA4-54D9-4F80-BDA4-0D7CEC6028B1

Q26772969-136F5F2A-26B3-40A3-8CED-E77E73DB23BC

Q26772969-1382D1F9-22E9-45AC-8970-9C8B587CD1CD

Q26772969-1A75B9B9-6A0C-447E-AC53-071AAFE25048

P31

Q26772969-4525541C-0A0C-43E7-AA8A-11EEFDBA7825

Q26772969-BC2C1D92-D6C1-4374-8C34-B4402137ED76

P3181

Q26772969-29C4E826-C609-4371-9206-3FD55CC948E5

P356

Q26772969-0D991BFC-C266-4A16-9881-B4B42B6D4CC1

P407

Q26772969-11B61476-5173-4F38-AF6C-38156936C808

P5008

Q26772969-B6DCAD40-583D-4109-8E4D-C8DE4400207F

P577

Q26772969-1B10F7CF-697A-43DC-A1B5-7455AD63B2A2

Q26772969-D65DD6DB-FF39-4CA5-B774-23C98C1E3DEA

P698

Q26772969-732C2995-48EB-4B49-BFBE-032FB6804175

P921

Q26772969-0685A01E-6619-4AFB-8B73-0BF4725D0CC6

Q26772969-1F4C10A5-1908-4B9E-8F71-12C561AD165D

Q26772969-2254F046-878C-4F79-A2C3-2D1B2F4DE496

Q26772969-2AF9540F-D676-4B4E-874F-59E89A1E87B3

Q26772969-474D0F2C-89B2-4B88-A2BB-446049E705B5

Q26772969-7ED26FD1-CA66-4882-80A5-6342E1EFE21A

Q26772969-ACA881A4-5672-42C4-BBBA-B19E3EC430F7

Q26772969-EE08782E-A4E2-4C56-8D42-C6CA5534E357

Q26772969-FC5B92F2-B684-4600-A7CF-1143F2A55068

Q26772969-FDFA6EB3-BCA9-4B13-822E-693C3CB59CD7

P932

Q26772969-DBE3A604-3B20-48F4-B7E7-20031AD603C3

P3181

P356

ONCOTARGET.7043

P1433

P1476

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

@en

P2093

Debora de Melo Gagliato

http://www.w3.org/2001/XMLSchema#string

Denis Leonardo Fontes Jardim

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Mario Sergio Pereira Marchesi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members

Trastuzumab containing regimens for early breast cancer

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Identification of heregulin, a specific activator of p185erbB2

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Cancer treatment and survivorship statistics, 2012

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

P31

scholarly article

P3181

3734796

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.7043

http://www.w3.org/2001/XMLSchema#string

P407

P5008

P577

2016-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26824988

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

membrane proteins

breast neoplasm

proto-oncogene proteins

tumor biomarkers

physiological phenomena

neoplasm proteins

P932

5325455

http://www.w3.org/2001/XMLSchema#string